Northern General Hospital, Sheffield Teaching Hospitals, Sheffield, UK.
Pain Physician. 2021 Mar;24(2):185-192.
Diagnostic injections (blocks) are a valuable tool in the management of chronic noncancer pain. By precise blockade of specific neural structures and observation of pain responses, pain mechanisms can be accurately defined. With such information, therapeutic procedures targeting neural structures are possible. Fibromyalgia is a disorder of pain processing with characteristic symptoms. The 2010 American College of Rheumatologists fibromyalgia diagnostic criteria evaluates these symptoms in a scoring system, allowing more objectivity in the diagnosis. We hypothesize that patients with fibromyalgia phenotype fulfilling the 2010 American College of Rheumatologists criteria may respond to diagnostic blocks differently when compared to patients without fibromyalgia phenotype.
This study was designed to establish whether diagnosis or suspected diagnosis of fibromyalgia should influence the decision to perform diagnostic blocks for chronic non-cancer pain.
A prospective observational research study was performed at our institution. IRAS project ID: 231514.
Tertiary pain clinic in the UK.
Patients were selected to receive diagnostic block by usual clinical assessment after which they were asked to consent to take part in the study. All participating patients completed the 2010 American College of Rheumatologists fibromyalgia diagnostic questionnaire prior to the diagnostic block. Patients were divided into 2 groups A and B based on the outcome of block - primary outcome. Group A experienced a 70% or greater improvement in pain severity following the block for the anticipated duration of action of the local anesthetic, Group B experienced a less than 70% reduction in pain. Statistical analysis between groups A and B was conducted by comparing categorical data, described as percentages, with the chi squared test. Ordinal variables such as Widespread pain index and Symptom severity score are presented as median and analyzed with Mann-Whitney test.
Seventy-seven patients were included in the study. Two patients were lost to follow-up. Of the 75 remaining patients, 44 received lumbar medial branch blocks, 19 genicular nerve blocks, 3 blocks to nerves supplying the sacroiliac joint, one suprascapular nerve block, and 6 cervical and 2 thoracic medial branch blocks. Group A contained 38 patients and group B contained 37 patients. There was no statistically significant difference in the prevalence of fibromyalgia screening questionnaire positive patients between groups A (13 out of 38 patients) and B (13 out of 37 patients), P = 0.93. There was no statistically significant difference in the prevalence of fibromyalgia screening questionnaire positive patients in subgroups undergoing the same type of diagnostic block (spinal pain and knee pain).
Selection of patients prior to inclusion in the study may introduce bias. Patients were selected by individual treating clinicians using usual clinical practice; however, the exact selection criteria were not standardized.
We conclude that after physician selection, the presence of fibromyalgia phenotype does not influence the outcome from diagnostic block. It is likely therefore that fibromyalgia phenotype should not influence the decision to perform diagnostic blocks if indicated based on assessment by an experienced pain physician.
诊断性注射(阻滞)是慢性非癌性疼痛管理中的一种有价值的工具。通过对特定神经结构的精确阻滞和观察疼痛反应,可以准确定义疼痛机制。有了这些信息,就可以针对神经结构进行治疗。纤维肌痛是一种以特征性症状为特征的疼痛处理障碍。2010 年美国风湿病学会纤维肌痛诊断标准通过评分系统评估这些症状,使诊断更加客观。我们假设,符合 2010 年美国风湿病学会标准的纤维肌痛表型患者在接受诊断性阻滞时的反应可能与无纤维肌痛表型的患者不同。
本研究旨在确定纤维肌痛的诊断或疑似诊断是否会影响对慢性非癌性疼痛进行诊断性阻滞的决策。
这是一项在我们机构进行的前瞻性观察性研究。IRAS 项目 ID:231514。
英国的一家三级疼痛诊所。
患者在接受常规临床评估后被选择接受诊断性阻滞,然后被要求同意参与研究。所有参与的患者在接受诊断性阻滞前都完成了 2010 年美国风湿病学会纤维肌痛诊断问卷。根据阻滞的预期局部麻醉作用持续时间,患者分为 A 组和 B 组(主要结局)。A 组的疼痛严重程度在阻滞后改善了 70%或以上,B 组的疼痛缓解程度低于 70%。通过比较分类数据(以百分比表示)和卡方检验对 A 组和 B 组之间进行统计学分析。广泛疼痛指数和症状严重程度评分等有序变量以中位数表示,并采用曼-惠特尼检验进行分析。
共有 77 名患者纳入研究。2 名患者失访。在 75 名剩余患者中,44 名接受了腰椎内侧支阻滞,19 名接受了关节内神经阻滞,3 名接受了供应骶髂关节的神经阻滞,1 名接受了肩胛上神经阻滞,6 名接受了颈椎和 2 名接受了胸椎内侧支阻滞。A 组包含 38 名患者,B 组包含 37 名患者。A 组(38 名患者中有 13 名)和 B 组(37 名患者中有 13 名)的纤维肌痛筛查问卷阳性患者的患病率之间无统计学显著差异,P = 0.93。在接受相同类型诊断性阻滞的亚组中(脊柱疼痛和膝关节疼痛),纤维肌痛筛查问卷阳性患者的患病率也无统计学显著差异。
在纳入研究之前选择患者可能会引入偏倚。患者由每位治疗医生根据常规临床实践选择;然而,具体的选择标准没有标准化。
我们的结论是,在医生选择之后,纤维肌痛表型的存在并不影响诊断性阻滞的结果。因此,如果基于经验丰富的疼痛医生的评估,纤维肌痛表型可能不应影响进行诊断性阻滞的决策。